Articles tagged with Type 1 Diabetes
Professor Len Harrison has been awarded the JDRF Australia Lifetime Research Achievement Award for his groundbreaking work on improving treatments for people with type 1 diabetes. His research aims to prevent or delay the onset of the disease, bringing hope for better therapies and treatments.
Research published in Diabetologia shows that pre-existing diabetes in pregnant women significantly increases the risk of fetal and infant death. The study found a four-and-a-half times higher risk of fetal death and an almost doubling of infant mortality compared to women without diabetes.
Researchers have identified adolescents with type 1 diabetes at risk of developing heart and kidney diseases through a simple urine test. The study found that normal variation in albumin levels can be an indicator of risk during adolescence.
New technology enabled scientists to prove that most people with type 1 diabetes have active beta cells producing insulin in response to food, contrary to previous thought. This finding has significant implications for understanding the biology of Type 1 diabetes and may lead to new therapies to preserve or replenish beta cells.
Joslin researchers found T cells, not B cells, contribute to beta cell proliferation in type 1 diabetes. Immune cells secrete inflammatory cytokines and chemokines that enhance beta cell growth.
The Joslin Diabetes Center will conduct a clinical trial to evaluate the benefits of allopurinol in reducing kidney function loss among people with type 1 diabetes. The five-year trial aims to determine if high serum uric acid levels are the cause of diabetic kidney disease.
A UK study found improved life expectancy for people with type 1 diabetes, particularly among younger individuals. The research suggests that this improvement should be reflected in life insurance policies, but gaps in life expectancy remain between the T1DM population and general populations.
A study of 1038 patients with type 1 diabetes reveals that social deprivation and poor blood sugar control are independent risk factors for mortality. Those with higher HbA1c levels and lower socioeconomic status were more likely to die from complications related to the disease.
The study found that sensor-augmented pump therapy significantly reduced the rate of severe and moderate hypoglycemia among patients with type 1 diabetes, particularly those with impaired awareness. The technology demonstrated potential to reduce the duration and frequency of significant hypoglycemia.
Research published at EASD annual meeting shows having children lowers mortality in people with type 1 diabetes, particularly for women. Mortality rates are significantly higher among women with diabetes compared to controls, but having offspring reduces this disparity.
A large European study suggests men with type 1 diabetes have better blood sugar control than women, especially in older age groups. Women tend to have higher HbA1c levels due to lower hemoglobin levels, which could explain the difference.
Researchers found that alefacept preserved the body's ability to produce its own insulin, with fewer episodes of hypoglycemia, while selectively targeting disease-causing T cells. The study suggests a potential new strategy for treating type 1 diabetes by restoring balance between immune cells.
A phase II study found that alefacept treatment significantly reduced insulin use and hypoglycemic events in newly diagnosed type 1 diabetics. The therapy targeted memory T-cells, preserving regulatory T-cells.
The new procedure, known as the CIT07 protocol, resulted in significantly improved islet cell function and enabled patients to discontinue daily insulin injections. The approach reduced inflammation and allowed for more efficient use of fewer islet cells.
Researchers discover STING's critical role in treating autoimmune diseases by evoking expression of enzyme IDO, which blocks immune attack on healthy body constituents. Mice with STING deficiency had no response to DNA nanoparticles, highlighting the protein's essential role in recognizing the molecule that senses DNA.
A phase II study tested thymoglobulin, an antithymocyte globulin treatment, in new-onset type 1 diabetic patients. While most younger patients showed decline in beta cell function, older patients experienced little change. The study did not meet its primary endpoint and may have identified biomarkers for safety and efficacy.
A recent study found that glucagon, a hormone involved in regulating appetite, fails to induce feelings of fullness in obese individuals. However, it successfully suppresses hunger pangs in people with type 1 diabetes, according to researchers from The Endocrine Society.
A recent clinical trial found that patients with new-onset type 1 diabetes treated with teplizumab exhibit greater preservation of C-peptide, a biomarker of islet cell function. Further analysis identified a discrete subset of treatment responders who demonstrated especially robust responses.
Four research projects, including insulin gene therapy and a revolutionary sensor platform, will receive funding from the Minnesota Partnership for Biotechnology and Medical Genomics to develop new therapies for diabetes management and prevention. The selected researchers were awarded $2 million in total.
Researchers found that adding foods rich in amino and fatty acids, such as leucine and omega-3 fatty acids, may help youth with Type 1 diabetes produce some of their own insulin for up to two years after diagnosis. This approach could benefit the lives of these children by reducing the risk of diabetes complications.
Researchers found that introducing solid foods before 4 months increases Type 1 diabetes risk, while breast-feeding reduces it. The study suggests parents wait until after 4 months and introduce solid foods by 6 months or soon after with breastfeeding to lower the risk.
A study published in JAMA Pediatrics found both early and late first exposure to solid food is associated with an increased risk of developing Type 1 diabetes. Early introduction to fruit and late introduction to rice/oat were linked to higher risk, while breastfeeding during wheat/barley introduction may decrease the risk.
A new study published in JAMA Pediatrics suggests that early childhood respiratory infections may be a potential risk factor for developing type 1 diabetes mellitus. The research found associations between respiratory infections during the first six months of life and later development of persistent islet autoimmunity.
Researchers at UC Irvine are working on two groundbreaking projects to treat Type 1 diabetes: islet cell transplantation using ultrapure algae membranes and the development of an accurate insulin sensor for real-time blood sugar monitoring. These innovations aim to improve treatment options and potentially cure the disease.
A decade-long study reveals that nearly 70% of children with multiple islet autoantibodies developed T1D within 10 years, highlighting the importance of pre-diabetes research. The study also found that progression of the disease was faster for those who showed the presence of antibodies at younger than three years old.
A study found that multiple islet autoantibodies predict a high rate of progression to type 1 diabetes, particularly among younger children and females. The researchers analyzed data from three cohort studies involving over 3,000 genetically at-risk children.
The TEDDY study has identified a unique perspective on which molecular and environmental factors contribute to type 1 diabetes. By parsing genetic mutations, scientists can better predict disease progression and identify potential protective factors.
Researchers are testing whether a drug called aldesleukin can reduce the number of insulin injections needed for type 1 diabetes patients. The trial aims to slow disease progression and give patients more control over their condition.
Researchers at the University of Missouri School of Medicine have discovered a potential cure for Type 1 diabetes by combining adult stem cells with a new drug. The discovery reveals that blood vessels are essential for insulin production and repairing them can help restore insulin-making cells.
Researchers have identified an immune protein called CD52 that can suppress the immune response and prevent or reverse type 1 diabetes. This discovery has wider implications for treating autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.
Researchers developed a biomaterial that successfully engrafted insulin-producing cells into diabetic mice, reversing symptoms in just 10 days. The material promotes blood vessel formation and allows cells to survive and function within the body.
A new study links type 1 diabetes to an increased risk of heart disease through the production of the inflammatory protein calprotectin, which fuels the buildup of artery-clogging plaque.
A major international TEDDY study found no evidence of a causal link between early viral infections and the rapid onset of Type 1 diabetes in young children. Despite analysis of over 8,000 children and blood samples, researchers discovered little association between viral infections and disease progression.
A study by University of Montreal researchers found a negative correlation between household income and glycated hemoglobin levels in children with type 1 diabetes. The difference in glycated hemoglobin levels corresponds to a doubling of the risk of eye damage, highlighting the need for greater support for low-income families
A new study by Joslin researchers found that dietary fat can impact glucose levels and insulin dosing for people with type 1 diabetes. The study's findings have significant implications for managing the condition, highlighting the need to consider both carbohydrates and fats in insulin calculations.
Youth with type 1 diabetes face increased risk of heart attacks, strokes, blindness, and kidney failure after transitioning to adult care without adequate support. The study found that nearly 80% of individuals had left pediatric care by age 21, highlighting the importance of effective transition planning.
Young people with Type 1 diabetes who transitioned from pediatric to adult care are 2.5 times more likely to have chronically high blood glucose levels, increasing the risk of heart attacks, strokes, and kidney failure. The estimated median age of patients when this transition occurred was 20.1 years.
A recent study published in Cell Metabolism reveals that a single mutation in the SIRT1 gene can cause type 1 diabetes in humans. The researchers identified a previously undocumented mutation that led to an amino acid substitution in the SIRT1 protein, resulting in high levels of blood sugar.
A study published in Cell Metabolism identified a single gene mutation in SIRT1 as a potential cause of type 1 diabetes. The research found that the mutated gene led to impaired beta cell function and increased susceptibility to diabetes.
The Benaroya Research Institute has established a T1D Exchange Biobank Operations Center with a $4.4 million grant from The Leona M. and Harry B. Helmsley Charitable Trust. This center will coordinate clinical study proposals and sample requests, facilitating research with thousands of participants.
Researchers found that white, non-Hispanic young adults with higher serum levels of vitamin D had about half the risk of developing Type 1 diabetes than those with lower levels. The study suggests that inadequate vitamin D intake may be an important risk factor for autoimmune diseases.
Researchers found a significant decrease in carotid intima-media thickness one year after islet transplant, indicating slower atherosclerosis progression. Patients achieved insulin independence and showed improved glycemic control.
The incidence of type 1 diabetes in Philadelphia children has increased by 29 percent over the past two decades, with black children ages 0-4 years at highest risk. The rapidly rising risk requires immediate attention due to often-delayed diagnosis and high mortality rates.
Researchers discovered that innate immune cells, particularly dendritic cells, trigger the activation of killer T-lymphocytes targeting pancreatic cells. The study sheds light on new ways to regulate the auto-immune reaction and offers potential therapeutic approaches for preventing Type 1 diabetes.
Researchers have identified a genetic variant associated with an increased risk of autoimmune diseases like type 1 diabetes. In a mouse model study, turning off the PTPN22 gene reduced the risk of autoimmune diabetes and increased regulatory T cells.
Drs. Christophe Benoist and Diane Mathis were awarded the 2012 Naomi Berrie Award for their contributions to understanding type 1 diabetes. They elucidated key immunological mechanisms, including T-cell priming and central tolerance, which may lead to prevention or reversal of the disease through immunization.
A six-year study found a correlation between vitamin D3 serum levels and subsequent incidence of Type 1 diabetes, suggesting a preventive role for vitamin D3 in this disease. Researchers estimate that achieving an optimal serum level of 25(OH)D at 50 ng/ml can lower the risk of developing type 1 diabetes by half.
Scientists have identified stem cells in the adult pancreas that can be turned into insulin-producing cells, offering a potential cure for type 1 diabetes. This breakthrough discovery provides further evidence of the existence of stem cells beyond embryos and may lead to new treatments for the condition.
Researchers from Benaroya Research Institute, Seattle Children's Research Institute, and University of Virginia are joining forces to study the genetic causes of Type 1 diabetes. The study aims to identify immunologic pathways involved in the disease, which can be targeted for diagnosis and therapy.
Researchers at Thomas Jefferson University found that normalizing the population of protective T regulatory cells in the pancreatic lymph nodes can regenerate insulin-producing beta cells and normalize blood sugar levels in diabetic mice. The study suggests a new approach to confront local autoimmune reactions in type 1 diabetes.
A Scottish study found people with type 1 diabetes have a higher risk of heart attacks, strokes, and premature death compared to the general population. The researchers also discovered that women are more at risk than men, with higher rates of cardiovascular events and deaths from any cause.
A new study suggests that oral insulin may prevent or delay the onset of type 1 diabetes among individuals with autoantibodies against insulin. The study found that participants who took oral insulin had a delayed development of type 1 diabetes compared to those who took placebo capsules. The delaying effect was attributed to the immun...
Researchers aim to develop a biologic cure for diabetes by addressing immunosuppression, poor islet viability, and implantation issues. The new funding will support the development of bioactive scaffolds and conformal coatings to protect implanted cells from the immune response.
A phase I clinical trial confirms that a generic vaccine can kill autoimmune cells targeting insulin-secreting cells, temporarily restoring insulin production in patients with type 1 diabetes. The treatment pathway has been validated in humans and shows early evidence of effectiveness.
Researchers found that continuous glucose monitoring devices and insulin pumps improve blood sugar levels and reduce time spent with high levels in patients with type 1 diabetes. These new technologies offer a more convenient alternative to traditional methods, but adherence is key to effectiveness.
The American College of Physicians developed a free curriculum to train internal medicine residents in identifying and eliminating wasteful treatment options. The high-value, cost-conscious care curriculum focuses on patient cases requiring careful analysis of benefits, harms, costs, and evidence-based decision making.
Researchers at UNC School of Medicine used injections of non-depleting antibodies to rapidly reverse the onset of Type I diabetes in mice. The treatment maintained disease remission indefinitely without harming the immune system, with some animals remaining free of diabetes after over 400 days.
A new study found that adding liraglutide to insulin therapy improves blood sugar control in obese adults with poorly controlled Type 1 diabetes. Patients also experienced significant weight loss and lower blood pressure.
Scientists at Joslin Diabetes Center have identified a new cause of cardiac damage after heart attacks in people with type 1 diabetes. A runaway autoimmune response triggered by alpha-myosin leads to chronic inflammation, cardiomyopathy, and heart failure. The study offers promising targets for future interventions to protect the heart.
A study by Joslin Diabetes Center found that a significant number of people with long-term type 1 diabetes developed little to no diabetic eye disease over time. The researchers hope to identify the factors behind this protection, which could lead to new treatments or prevention strategies.